Regio- and Stereoselective Photoredox-Catalyzed Atom Transfer Radical Addition of Thiosulfonates to Aryl Alkynes
作者:Zhiyuan Peng、Haolin Yin、Hui Zhang、Tiezheng Jia
DOI:10.1021/acs.orglett.0c01982
日期:2020.8.7
regioselectivity of atom transfer radical addition (ATRA) to alkynes remains a highly desirable yet unachieved challenge. Guided by computational predictions, thiosulfonates were found herein as a tunable radical precursor for thiyl radicals instead of well-recognized sulfonyl radicals. Merging such a finding with ATRA to phenylacetylenes leads to a highly regio- and stereoselective approach to (E)-β-arylsulfonylvinyl
Pd-PEPPSI-IPent<sup>Cl</sup>: a new highly efficient ligand-free and recyclable catalyst system for the synthesis of 2-substituted indoles via domino copper-free Sonogashira coupling/cyclization
initiation), is used as a first class recyclable catalytic system for the synthesis of 2-substituted indoles via domino copper-free Sonogashira coupling/cyclization. The catalyst showed a greater performance in the cascade reaction of various 2-bromo anilines with different terminalacetylenes under mild (60 °C) and green conditions (ethanol : water) even in the absence of a copper catalyst and an
Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1
作者:Yujeong Lee、Yoshiyuki Onishi、Lisa McPherson、Anna M. Kietrys、Marian Hebenbrock、Yong Woong Jun、Ishani Das、Shanthi Adimoolam、Debin Ji、Michael G. Mohsen、James M. Ford、Eric T. Kool
DOI:10.1021/acschembio.2c00038
日期:2022.8.19
Impaired DNA repair activity has been shown to greatly increase rates of cancer clinically. It has been hypothesized that upregulating repair activity in susceptible individuals may be a useful strategy for inhibiting tumorigenesis. Here, we report that selected tyrosine kinase (TK) inhibitors including nilotinib, employed clinically in the treatment of chronic myeloid leukemia, are activators of the
INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS
申请人:Disarm Therapeutics, Inc.
公开号:US20220008405A1
公开(公告)日:2022-01-13
The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and a neuroprotective agent.
INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR
申请人:Disarm Therapeutics, Inc.
公开号:US20220072019A1
公开(公告)日:2022-03-10
The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.